Compare PMCB & JZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PMCB | JZ |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 8.2M |
| IPO Year | N/A | 2022 |
| Metric | PMCB | JZ |
|---|---|---|
| Price | $0.94 | $1.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 386.6K | 30.2K |
| Earning Date | 03-16-2026 | 10-16-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,589,020.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.63 | $0.90 |
| 52 Week High | $1.90 | $14.60 |
| Indicator | PMCB | JZ |
|---|---|---|
| Relative Strength Index (RSI) | 57.10 | 34.82 |
| Support Level | $0.84 | $0.93 |
| Resistance Level | $1.00 | $1.00 |
| Average True Range (ATR) | 0.09 | 0.11 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 75.90 | 18.33 |
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
Jianzhi Education Technology Group Co Ltd engages in developing educational content to fulfill the massive demand for high-quality, professional development training resources in China. The company and its subsidiaries VIE and VIEs generate subscription revenue through selling subscriptions to online learning platforms, higher education institutions, and other institutional customers under a B2B2C model mainly through the platform of Sentu Academy; offering subscriptions concerning educational content in mobile video packages directly to end users under a B2C model through the platforms such as Fish Learning or Light Class, etc. It has two operating segments: Educational content services and other services and IT-related solution services.